$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—OGN, MMTX, VRE, and ESQ

NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating

GlobeNewsWire • May 5, 2026

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • May 4, 2026

Organon Reports Results for the First Quarter Ended March 31, 2026

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue in $ millions   Q1 2026   Q1 2025   VPY   VPY ex-FX Women's Health   $ 389   $ 463   (16)%   (19)% General Medicines                 Biosimilars     173     141   23%   21% Established Brands     880     887   (1)%   (7)% Other (1)     18     22   (15)%   (21)% Revenue   $ 1,460   $ 1,513   (4)%   (9)%     Totals may not foot due to rounding.

Business Wire • Apr 30, 2026

Organon (OGN) Q1 Earnings and Revenues Miss Estimates

Organon (OGN) came out with quarterly earnings of $0.71 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $1.02 per share a year ago.

Zacks Investment Research • Apr 30, 2026

Organon (OGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Apr 30, 2026

Organon Cancels First Quarter Earnings Call

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue.

Business Wire • Apr 29, 2026

Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon & Co. - OGN

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Organon & Co. (NYSE: OGN) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Organon will receive $14.00 in cash for each share of Organon that they own. KSF is seeking to determine whether this consideration and the process that led to it.

Business Wire • Apr 28, 2026

Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal

Expand NYSE: OGN Organon & Co. Today's Change (16.87%) $1.90 Current Price $13.16 Key Data Points Market Cap $2.9B Day's Range $13.15 - $13.24 52wk Range $5.69 - $13.24 Volume 134M Avg Vol 5.8M Gross Margin 53.59% Dividend Yield 0.71% Organon (OGN +16.87%), a women's health therapies specialist, closed Monday at $13.16, up 16.87%. The stock is jumping after premarket news that Sun Pharmaceutical Industries agreed to acquire Organon in an all-cash deal.

The Motley Fool • Apr 27, 2026

Why is Sun Pharma betting $11.75B on a struggling US drugmaker?

In one of the biggest outbound acquisitions ever attempted by an Indian company, Sun Pharmaceutical Industries has decided to buy Organon & Co. for $14 a share in an all-cash deal valued at $11.8 billion The logic of the deal is easy to state and harder to execute as Sun is not buying a fast-growing asset, but a scaled global platform with meaningful cash flow, a large commercial footprint and a huge debt load. Sun is planning to expand in women's health, biosimilars and innovative medicines, while Organon brings more than 70 products across women's health and general medicines in 140 countries.

Invezz • Apr 27, 2026

Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.

India's Sun Pharmaceutical Industries agrees to buy the women's health company for $14 a share in an all-cash deal.

Barrons • Apr 27, 2026